Dave Conapitski

Associate Director at Centocor - , N/A, US

Dave Conapitski's Colleagues at Centocor
Alison Rogers

Associate Scientist II

Contact Alison Rogers

John Gray

Associate Director

Contact John Gray

Luke Moyer

Sr. Clinical Supplies Coordinator

Contact Luke Moyer

Gerald Curran

Manufacturing Supervisor

Contact Gerald Curran

John Zappitelli

planner/supervisor/engineering

Contact John Zappitelli

View All Dave Conapitski's Colleagues
Dave Conapitski's Contact Details
HQ
610-651-6000
Location
Greater Philadelphia
Company
Centocor
Dave Conapitski's Company Details
Centocor logo, Centocor contact details

Centocor

, N/A, US • 1000 - 4999 Employees
BioTech/Drugs

Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.

BioTech/Drugs Commercial Physical Research Biotechnology
Details about Centocor
Frequently Asked Questions about Dave Conapitski
Dave Conapitski currently works for Centocor.
Dave Conapitski's role at Centocor is Associate Director.
Dave Conapitski's email address is ***@centocor.com. To view Dave Conapitski's full email address, please signup to ConnectPlex.
Dave Conapitski works in the BioTech/Drugs industry.
Dave Conapitski's colleagues at Centocor are Alison Rogers, Lynnmarie Harkins, John Gray, Jeffrey Glenn, Luke Moyer, Gerald Curran, John Zappitelli and others.
Dave Conapitski's phone number is 610-651-6000
See more information about Dave Conapitski